Coronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOT-HEART Study

Michelle C. Williams, MBChB, PhD,a,b Alastair J. Moss, MD,a Marc Dweck, MBChB, PhD,a,b Philip D. Adamson, MD, PhD,a,c Shirjel Alam, MD,a Amanda Hunter, MD,a Anoop S.V. Shah, MD,a Tania Pawade, MD,a Jonathan R. Weir-McCall, MBChB, PhD,d Giles Roditi, MD,e Edwin J.R. van Beek, MD, PhD,b David E. Newby, MD, PhD,a,b Edward D. Nicol, MDf,g

ABSTRACT

BACKGROUND Unlike most noninvasive imaging modalities, coronary computed tomography angiography can characterize subtypes of atherosclerotic plaque.

OBJECTIVES The purpose of this study was to investigate the prognostic implications of adverse coronary plaque characteristics in patients with suspected coronary artery disease.

METHODS In this SCOT-HEART (Scottish COmputed Tomography of the HEART Trial) post hoc analysis, the presence of adverse plaque (positive remodeling or low attenuation plaque), obstructive disease, and coronary artery calcification within 15 coronary segments was assessed on coronary computed tomography angiography of 1,769 patients who were followed-up for 5 years.

RESULTS Among study participants (mean age 58 ± 10 years; 56% male), 608 (34%) patients had 1 or more adverse plaque features. Coronary heart disease death or nonfatal myocardial infarction was 3 times more frequent in patients with adverse plaque (n = 25 of 608 [4.1%] vs. n = 16 of 1,161 [1.4%]; p < 0.001; hazard ratio [HR]: 3.01; 95% confidence interval (CI): 1.61 to 5.63; p = 0.001) and was twice as frequent in those with obstructive disease (n = 22 of 452 [4.9%] vs. n = 16 of 671 [2.4%]; p = 0.024; HR: 1.99; 95% CI: 1.05 to 3.79; p = 0.036). Patients with both obstructive disease and adverse plaque had the highest event rate, with a 10-fold increase in coronary heart disease death or nonfatal myocardial infarction compared with patients with normal coronary arteries (HR: 11.50; 95% CI: 3.39 to 39.04; p < 0.001). However, these associations were not independent of coronary artery calcium score, a surrogate measure of coronary plaque burden.

CONCLUSIONS Adverse coronary plaque characteristics and overall calcified plaque burden confer an increased risk of coronary heart disease death or nonfatal myocardial infarction. (Scottish COmputed Tomography of the HEART Trial [SCOT-HEART]; NCT01149590) (J Am Coll Cardiol 2019;73:291–301) © 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Pathological studies in patients with myocardial infarction have identified an association between plaque rupture and adverse plaque characteristics that includes positive remodeling, a large necrotic core, microcalcification, and a thin fibrous cap (1). Correlates of these features have been described for noninvasive imaging with coronary CTA and include the presence of positive remodeling, low attenuation plaque, spotty calcification, and the “napkin ring” sign (2). These plaque characteristics are associated with an increased risk of subsequent acute coronary syndromes (2–4). Recent data have suggested that positive remodeling and low attenuation plaque in particular provide the most useful prognostic information (2,5), although it remains unclear whether this is of incremental value to traditional cardiovascular risk factors or coronary plaque burden.

In the SCOT-HEART (Scottish COmputed Tomography of the HEART) prospective, multicenter, randomized controlled trial of patients with stable chest pain, the addition of coronary CTA to routine care led to improved diagnostic certainty and patient care that ultimately reduced the rate of coronary heart disease death or nonfatal myocardial infarction (6–8). These benefits were largely attributable to subsequent changes in patient management and treatment, which had been guided by the presence of obstructive or nonobstructive coronary artery disease as determined by coronary CTA. However, it may be that further risk stratification and targeted intensification of therapy in patients with adverse plaque characteristics could achieve additional benefits that go beyond the presence of obstructive or nonobstructive coronary artery disease.

In this secondary analysis of the SCOT-HEART trial, we aimed to determine the extent of adverse coronary artery plaque characteristics on coronary CTA and their association with subsequent clinical outcomes. If confirmed, the identification of these coronary artery plaque characteristics may help risk stratification and guide the intensity of therapy.

**METHODS**

**STUDY DESIGN.** The SCOT-HEART trial was a multicenter randomized controlled trial of coronary CTA in outpatients with suspected angina pectoris due to coronary artery disease (9). The primary results have been reported previously (6–8). This paper presents a secondary post hoc analysis of the SCOT-HEART study.

**PARTICIPANTS.** In brief, 4,146 patients who attended the cardiology outpatient clinic were randomized to standard care alone or standard care plus coronary CTA, and were followed up for symptoms, management, and outcomes. Of the 2,073 participants who were randomized to the intervention arm, 1,778 underwent coronary CTA. Coronary CTA and noncontrast imaging for calcium scoring was performed as described previously (7). Cardiovascular risk was assessed using the ASSIGN (ASsessing cardiovascular risk using Scottish Intercollegiate Guideline Network guidelines) score. This score has been validated for the Scottish population and, in addition to traditional cardiovascular risk factors, incorporates social deprivation and family history of cardiovascular disease (10).

**ASSESSMENT OF COMPUTED TOMOGRAPHY IMAGES.** Coronary artery calcium score was assessed on noncontrast computed tomography (CT) using the Agatston scoring method as previously described (11). Coronary artery calcium scores were classified into 4 categories (0, 1 to 99, 100 to 399, and ≥400 Agatston units [AU]).

On coronary CTA images, per-segment assessment of atherosclerotic plaque was performed using a...
15-segment model by 6 trained observers, with complex cases classified by consensus (12). Normal coronary arteries were defined by the absence of obstructive or nonobstructive atherosclerotic plaque. Nonobstructive coronary artery disease was defined by the presence of atherosclerotic plaque occupying a cross-sectional area stenosis $\leq 70\%$. Obstructive coronary artery disease was defined as a stenosis $>70\%$ in 1 or more major epicardial vessel or $>50\%$ in the left main stem. Observer agreement for the identification of coronary artery disease on coronary CTA and coronary artery calcium score in the SCOT-HEART study has previously been shown to be excellent (13).

For each segment, the presence or absence of 4 coronary artery plaque characteristics was assessed (Figure 1): positive remodeling, low attenuation plaque, spotty calcification, and the “napkin ring” sign. Positive remodeling was defined as an outer vessel diameter that was 10% greater than the mean of the diameter of the segments immediately proximal and distal to the plaque (3). Low-attenuation plaque was defined as a focal central area of plaque with an attenuation density of $< 30$ Hounsfield Units (14). Spotty calcification was defined as focal calcification within the coronary artery wall $< 3$ mm in maximum diameter (3). The “napkin ring” sign was defined, as previously described, as a central area of low-attenuation plaque that had a peripheral rim of high attenuation (15). Observer agreement for the assessment of coronary artery plaque characteristics has overall been shown to be fair (16).

An individual adverse plaque was defined as one with positive remodeling or low-attenuation plaque, as described previously by Motoyama et al. (3). Patients with 1 or more adverse plaques were defined as having adverse plaque.

**CLINICAL MANAGEMENT AND OUTCOMES.** Outcome information including invasive coronary angiography and coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery) was obtained from the electronic Data Research and Innovation Service of the National Health Service (NHS) Scotland and, where appropriate, confirmed by review of the patient health records. Categorization of outcomes was performed blinded to the coronary CTA or other study data. The primary clinical endpoint for this substudy was the occurrence of coronary heart disease death or nonfatal myocardial infarction. Outcome data were updated in March 2018 (6).

**STATISTICAL ANALYSIS.** Statistical analysis was performed using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria). Normally distributed quantitative variables are presented with mean ± SD. Non-normally distributed data are presented with median and interquartile range (IQR). Statistical significance was assessed using Pearson’s chi-square test, Fisher exact test, Student’s t-test, Mann-Whitney U test, Kruskal-Wallis test, or analysis of variance as appropriate. Outcome data investigating whether the presence of adverse plaque characteristics predicted coronary heart disease death or nonfatal myocardial infarction in patients with nonobstructive disease were analyzed using Cox proportional hazards regression and presented graphically using cumulative incidence plots. A time-to-event analysis was performed using coronary heart disease death or nonfatal myocardial infarction as the endpoint, with the primary independent variable

![FIGURE 1 Coronary Plaque Characteristics Identified on Computed Tomography Coronary Angiography](image)
**TABLE 1** Characteristics of Study Participants

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All Participants (N = 1,769)</th>
<th>Participants Without Adverse Plaque (n = 1,161)</th>
<th>Participants With Adverse Plaque (n = 608)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>997 (56)</td>
<td>545 (47)</td>
<td>452 (74)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age, yrs</td>
<td>57.6 ± 9.5</td>
<td>55.9 ± 9.8</td>
<td>60.8 ± 7.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>29.6 ± 5.5</td>
<td>30.0 ± 5.8</td>
<td>28.8 ± 4.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>34 (1.9)</td>
<td>20 (1.7)</td>
<td>14 (2.3)</td>
<td>0.399</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>330 (19)</td>
<td>208 (18)</td>
<td>122 (20)</td>
<td></td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>593 (34)</td>
<td>357 (31)</td>
<td>236 (39)</td>
<td></td>
</tr>
<tr>
<td>Nonsmoker</td>
<td>845 (48)</td>
<td>595 (51)</td>
<td>250 (41)</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>608 (35)</td>
<td>373 (32)</td>
<td>235 (39)</td>
<td>0.005</td>
</tr>
<tr>
<td>Anginal symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous PAD</td>
<td>31 (1.8)</td>
<td>19 (1.6)</td>
<td>12 (2)</td>
<td>0.608</td>
</tr>
<tr>
<td>Diabetes</td>
<td>196 (11)</td>
<td>128 (11)</td>
<td>68 (11)</td>
<td>0.919</td>
</tr>
<tr>
<td>Family history of CHD</td>
<td>765 (43)</td>
<td>507 (44)</td>
<td>258 (42)</td>
<td>0.552</td>
</tr>
<tr>
<td>Previous CHD</td>
<td>178 (10)</td>
<td>75 (6.5)</td>
<td>103 (17)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Coronary artery calcium score</td>
<td>21 [0–230]</td>
<td>0 [0–34]</td>
<td>281 (89–775)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Values are n (%), mean ± SD, or median [interquartile range]. Values in **bold** indicate statistical significance.

**ASSIGN** = Assessing cardiovascular risk using Scottish Intercollegiate Guidelines Network guidelines; CHD = coronary heart disease; PAD = peripheral arterial disease.

---

**TABLE 2** Frequency of Plaque Characteristics in Each of the 15 Coronary Artery Segments

<table>
<thead>
<tr>
<th>Coronary Segment</th>
<th>Adverse Plaque*</th>
<th>Positive Remodeling</th>
<th>Low-Attenuation Plaque</th>
<th>Spotty Calcification</th>
<th>Napkin Ring Sign</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left main stem</td>
<td>60 (3.4)</td>
<td>59 (3.3)</td>
<td>12 (0.7)</td>
<td>13 (0.7)</td>
<td>5 (0.3)</td>
</tr>
<tr>
<td>Prox LAD</td>
<td>388 (21.9)</td>
<td>385 (21.8)</td>
<td>78 (4.4)</td>
<td>117 (6.6)</td>
<td>33 (1.9)</td>
</tr>
<tr>
<td>Mid LAD</td>
<td>234 (13.2)</td>
<td>224 (12.7)</td>
<td>50 (2.8)</td>
<td>84 (4.7)</td>
<td>13 (0.7)</td>
</tr>
<tr>
<td>Dist LAD</td>
<td>21 (1.2)</td>
<td>19 (1.1)</td>
<td>5 (0.3)</td>
<td>14 (0.8)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>D1</td>
<td>19 (1.1)</td>
<td>19 (1.1)</td>
<td>1 (0.1)</td>
<td>20 (1.1)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>D2</td>
<td>5 (0.3)</td>
<td>5 (0.3)</td>
<td>0 (0)</td>
<td>8 (0.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Prox CX</td>
<td>109 (6.2)</td>
<td>106 (6.0)</td>
<td>18 (1.0)</td>
<td>39 (2.2)</td>
<td>6 (0.3)</td>
</tr>
<tr>
<td>OM1</td>
<td>27 (1.5)</td>
<td>26 (1.5)</td>
<td>4 (0.2)</td>
<td>13 (0.7)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>AV CX</td>
<td>11 (0.6)</td>
<td>11 (0.6)</td>
<td>1 (0.1)</td>
<td>4 (0.2)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>OM 2</td>
<td>1 (0.1)</td>
<td>1 (0.1)</td>
<td>0 (0)</td>
<td>2 (0.1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Mid dist CX</td>
<td>5 (0.3)</td>
<td>5 (0.3)</td>
<td>0 (0)</td>
<td>1 (0.1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Prox RCA</td>
<td>116 (6.6)</td>
<td>112 (6.3)</td>
<td>20 (1.1)</td>
<td>56 (3.2)</td>
<td>6 (0.3)</td>
</tr>
<tr>
<td>Mid RCA</td>
<td>132 (7.5)</td>
<td>130 (7.3)</td>
<td>19 (1.1)</td>
<td>63 (3.6)</td>
<td>10 (0.6)</td>
</tr>
<tr>
<td>Distal RCA</td>
<td>51 (2.9)</td>
<td>51 (2.9)</td>
<td>4 (0.2)</td>
<td>25 (1.4)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>RCA/CX PD</td>
<td>10 (0.6)</td>
<td>10 (0.6)</td>
<td>1 (0.1)</td>
<td>13 (0.7)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Values are n (%). *Positive remodeling or low-attenuation plaque. 11 or more plaque features per-vessel. AV = atrioventricular; CX = circumflex; D1 = first diagonal; D2 = second diagonal; LAD = left anterior descending; LM = left main; OM1 = obtuse marginal; PD = posterior descending; Prox = proximal; RCA = right coronary artery.

---

Of the 1,778 individuals who underwent a coronary CTA, 1,769 participants had images that were available and of suitable quality for analysis (**Online Figure 1**). Patients had a mean age of 58 ± 10 years, and 56% were male with a range of cardiovascular risk factors and symptoms (**Table 1**). Of these patients, 37% (n = 646) had normal coronary arteries, 38% (n = 671) had nonobstructive coronary artery disease, and 26% (n = 452) had obstructive coronary artery disease. Coronary heart disease death or nonfatal myocardial infarction occurred in 41 patients (2.3%) over a median of 4.7 years of follow-up (IQR: 4.0 to 5.7 years).

**PLAQUE CHARACTERISTICS.** Coronary CTA characteristics of atherosclerotic plaque were assessed in 26,535 segments in 1,769 patients. This demonstrated positive remodeling in 1,163 segments (4.4%), low attenuation plaque in 213 segments (0.8%), spotty calcification in 472 segments (1.8%), and the napkin ring sign in 78 segments (0.3%). All plaque characteristics were more common in the proximal coronary artery segments, in particular, the proximal left anterior descending coronary artery (**Table 2, Online Tables 1 to 4**).

Adverse plaques were present in 608 (34%) patients. Patients with adverse plaques were older, had a higher body mass index, and were more likely to be male. They were also more likely to have a previous history of coronary heart disease or hypertension, to be a smoker, or to have typical angina (**Table 1, Online Table 5**). Patients with adverse plaques had a higher cardiovascular risk score and higher calcium score. Coronary heart disease death or nonfatal myocardial infarction was 3 times more frequent in patients with adverse plaque compared to those without (n = 25 of 608 [4.1%] vs. n = 16 of 1,161 [1.4%]; p < 0.001; HR: 3.01; 95% CI: 1.61 to 5.63; p = 0.001) (**Figure 2**).
events occurred in patients with adverse plaques in
the proximal segments rather than the mid and distal
segments (n = 23 of 489 [4.7%] vs. n = 2 of 119 [1.7%];
p = 0.197). Adverse plaque features appeared to have
a greater prognostic value in women and those under
the age of 60 years, with a body mass index
>30 kg/m² or with a lower cardiovascular risk score,
but these differences were not statistically signi-
cificant (Online Table 6). The presence of 1 or more
segments of spotty calcification or the napkin ring sign was not
associated with a difference in coronary heart disease
death or nonfatal myocardial infarction on per-
patient assessment (Online Tables 3 and 7).

**CORONARY ARTERY STENOSIS.** Patients with
obstructive coronary artery disease were twice as
likely to experience coronary heart disease death or
nonfatal myocardial infarction (n = 22 of 452 [4.9%])
than patients with nonobstructive disease (n = 16 of
671 [2.4%]; chi-square p = 0.024; HR: 1.99; 95% CI:
1.05 to 3.79; p = 0.036). Patients with obstructive
coronary artery disease were also more likely to
undergo coronary revascularization (n = 215 of
452 [48%] vs. n = 35 of 671 [5%]; p < 0.001) and be
prescribed preventative medications at 6 weeks
(n = 427 of 452 [95%] vs. n = 538 of 671 [80%];
p < 0.001) than patients with nonobstructive disease.

Adverse plaques were observed in 40% of patients
with nonobstructive disease (n = 268 of 671) and
three-quarters of patients with obstructive coronary
artery disease (n = 340 of 452). Patients with both
obstructive disease and adverse plaque had the worst
outcome during follow-up (Figure 3). Although the
presence of adverse plaque is suggestive of a worse
prognosis at 2 years in patients with nonobstructive
disease, at 5 years the outcomes of patients with
nonobstructive disease and obstructive disease
without adverse plaque were similar (Figure 3).

Indeed, compared with patients with normal coro-
nary arteries, patients with obstructive disease and
adverse plaque had a >10-fold increase in the rate of
coronary heart disease death or nonfatal myocardial
infarction at 5 years (Table 3).

**CORONARY ARTERY CALCIUM SCORE.** Patients with
a coronary artery calcium score $≥1,000 AU had a
13-fold increase in coronary heart disease death or
nonfatal myocardial infarction compared with
**FIGURE 3** Coronary Heart Disease Death and Nonfatal Myocardial Infarction in Patients With Different Stenosis Severity and Coronary Artery Plaque Characteristics

![Cumulative incidence plot for coronary heart disease death and nonfatal myocardial infarction in patients with normal coronary arteries, nonobstructive disease, and obstructive disease and in normal coronary arteries, nonobstructive disease with and without adverse plaque characteristics, and obstructive disease with and without adverse plaque features. AP = adverse plaque; other abbreviations as in Figure 2.](image)

<table>
<thead>
<tr>
<th>Stenosis Severity</th>
<th>Follow-Up (Years)</th>
<th>Number at risk: n (%)</th>
<th>Proportion with CHD Death/Non-Fatal MI (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Normal</td>
<td>646 (100)</td>
<td>644 (100)</td>
<td>641 (99)</td>
</tr>
<tr>
<td>Non-obstructive</td>
<td>671 (100)</td>
<td>665 (99)</td>
<td>658 (98)</td>
</tr>
<tr>
<td>Obstructive</td>
<td>452 (100)</td>
<td>442 (98)</td>
<td>437 (97)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stenosis Severity</th>
<th>Follow-Up (Years)</th>
<th>Number at risk: n (%)</th>
<th>Proportion with CHD Death/Non-Fatal MI (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Normal</td>
<td>646 (100)</td>
<td>644 (100)</td>
<td>641 (99)</td>
</tr>
<tr>
<td>Non-obstructive</td>
<td>403 (100)</td>
<td>399 (99)</td>
<td>396 (98)</td>
</tr>
<tr>
<td>Obstructive</td>
<td>112 (100)</td>
<td>110 (98)</td>
<td>109 (97)</td>
</tr>
<tr>
<td>Non-obstructive</td>
<td>268 (100)</td>
<td>266 (99)</td>
<td>262 (98)</td>
</tr>
<tr>
<td>Obstructive</td>
<td>340 (100)</td>
<td>332 (98)</td>
<td>328 (96)</td>
</tr>
</tbody>
</table>

* Cumulative incidence plot for coronary heart disease death and nonfatal myocardial infarction in patients (top) with normal coronary arteries, nonobstructive disease, and obstructive disease and in (bottom) normal coronary arteries, nonobstructive disease with and without adverse plaque characteristics, and obstructive disease with and without adverse plaque features. AP = adverse plaque; other abbreviations as in Figure 2.
patients without coronary artery calcification. There was a clear gradation of risk, with calcification associated with increasing risk (Figure 4). Patients with obstructive coronary artery disease had an 8-fold higher coronary artery calcium score than patients with nonobstructive coronary artery disease (435 AU [IQR: 138 to 1,127 AU] vs. 54 AU [IQR: 12 to 190 AU]; p < 0.001). In multivariable analysis, the presence of both adverse plaque and obstructive plaque were dependent on coronary artery calcium score as a predictor of coronary heart disease death or nonfatal myocardial infarction (Table 4, Online Table 8).

There was no difference in the risk of events in patients with or without adverse plaque who had a CACS >100 AU. For patients with a CACS <100 AU, those with adverse plaque were at an increased risk of coronary heart disease death or nonfatal myocardial infarction compared with patients without adverse plaque (HR: 3.38; 95% CI: 1.13 to 10.08; p = 0.03).

**DISCUSSION**

In a large, multicenter, prospective study of coronary CTA, we demonstrated that adverse coronary plaque characteristics are associated with a tripling of the risk of coronary heart disease death or nonfatal myocardial infarction. The presence of obstructive disease was also a major predictor of risk, with the combination of adverse plaque with obstructive disease appearing to confer the greatest risk (Central Illustration). At 5 years, the risk of coronary heart disease death or nonfatal myocardial infarction was similar in patients with obstructive disease without adverse plaque and nonobstructive disease with or without adverse plaque. However, overall, the only independent predictor of risk was the coronary artery calcium score, a surrogate measure of overall plaque burden. These results suggest that although plaque composition and its hemodynamic consequences are associated with future myocardial infarction, the predominant factor governing patient outcomes is the burden of coronary atherosclerosis.

Adverse coronary plaque is associated with subsequent cardiovascular events in patients with stable coronary artery disease (2,4,5,17). In keeping with previous work (2,3,17-19), we found that the plaque characteristics that were the most helpful in predicting future coronary events were positive remodeling and low-attenuation plaque. These CT characteristics are markers of pathological vulnerability (20), and are potential culprit lesions for subsequent acute coronary events. Motoyama et al. (2) identified that the presence of adverse plaque was predictive of acute coronary syndrome at 4 years in a study of 3,158 patients with 88 events (2.8%). In the PROMISE (Prospective Multicentre Imaging Study for Evaluation of Chest Pain) trial, adverse plaques were present in 15% of patients and were associated with an increased risk of the combined endpoint of death, myocardial infarction, or unstable angina (21). However, overall adverse plaques have a low positive predictive value for the identification of subsequent coronary events. This is in keeping with the known theory of continuous plaque remodeling, where adverse plaques may stabilize with or without sub-clinical rupture, rather than cause a clinically apparent acute coronary syndrome.

Acute myocardial infarction occurs when there is rupture or erosion of a coronary atherosclerotic plaque and there is associated thrombus formation causing vessel occlusion (22). The presence of pre-existing flow limitation due to obstructive atheroma is not a prerequisite for this process. Indeed, it should be remembered that the majority (~80%) of myocardial infarctions are attributable to nonobstructive coronary plaques on antecedent angiography (23). Moreover, the risk of future myocardial infarction is similar whether the coronary plaque causes 50% to 85% or >85% luminal stenosis (24). A nested case-control study of patients without known coronary artery disease within the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicentre) registry identified that >65% of patients who developed acute coronary syndromes had non-obstructive disease on their baseline coronary CTA (25). This reflects the important nature of the biology

<table>
<thead>
<tr>
<th>TABLE 3 Univariable and Multivariable Analysis for Coronary Heart Disease Death or Nonfatal Myocardial Infarction Compared With Patients With Normal Coronary Arteries</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Nonobstructive disease without adverse plaque</td>
</tr>
<tr>
<td>Nonobstructive disease with adverse plaque</td>
</tr>
<tr>
<td>Obstructive disease without adverse plaque</td>
</tr>
<tr>
<td>Obstructive disease with adverse plaque</td>
</tr>
<tr>
<td>Coronary artery calcium score</td>
</tr>
<tr>
<td>Cardiovascular risk score</td>
</tr>
</tbody>
</table>

Values are hazard ratio (95% confidence interval). Values in bold indicate statistical significance. *Log rank statistic 27.29, p = 0.001; Harrell’s C-statistic 0.728 (standard error = 0.046). Adverse plaque defined as the presence of positive remodeling or low-attenuation plaque. §ASSIGN score, per doubling of cardiovascular risk score.
of the atherosclerotic plaque rather than the functional consequence of luminal stenosis (26). For the prediction of subsequent coronary events, the presence of atherosclerotic plaque is more important than the presence of coronary stenoses. Indeed, in our study, patients with a combination of both obstructive coronary artery disease and adverse plaque had the worst outcomes. Moreover, patients with non-obstructive disease and adverse plaque had similar outcomes to patients with obstructive disease without adverse plaque. Thus, our study provides evidence that coronary artery disease should no longer be defined based on luminal severity, but instead by the volume and type of disease.

When examined across the cohort as a whole, adverse plaques did not provide independent prognostic information when CT calcium scoring was included. CT calcium scoring is a surrogate marker of plaque burden, and its prognostic utility has been established in large studies of symptomatic and asymptomatic patients (27,28). It is likely that patients with higher plaque burden are more likely to have adverse plaques and are more likely to have severe coronary artery stenoses. Few studies have assessed the clinical implications of this overlap. A small study of 339 patients with suspected coronary artery disease found that both adverse plaques and CT calcium score were independent predictors of cardiac events at 2 years (29). Clearly, the greater the burden of disease, the greater the risk of events. However, for the individual patient, the assessment of coronary artery calcium alone is not sufficient to guide management, as the presence and volume of coronary artery calcification is not directly related to the degree of coronary artery stenosis and cannot

![Cumulative incidence plots of the effect of different severity of coronary artery calcification on subsequent coronary heart disease death or nonfatal myocardial infarction. Abbreviations as in Figure 2.](image-url)
inform on the pathophysiological status of the atherosclerotic plaque (30). Indeed, in the PROMISE study, coronary CTA provided better prognostic discrimination compared to coronary artery calcium score (31). Intriguingly, we also observed that adverse plaque was particularly discriminatory in patients with a low calcium score, reaffirming the concept that calcification is a healing or protective response to coronary atherosclerosis and that large areas of calcification are associated with plaque stabilization.

It is perhaps not surprising that the identification of plaque characteristics at a single time point by coronary CTA may not be sufficient to predict future events in long-term follow-up. Atherosclerotic plaque undergoes continuous remodeling driven by a variety of genetic and environmental factors, and we know that medications, such as statins, alter the constituents of atherosclerotic plaque (32). Autopsy studies show that atherosclerosis is present in young people (33) and nomograms for CT calcium score (28) and plaque burden (34) are in clinical use. Concerns have been raised about overmedicating patients with the routine use of preventative therapies for patients with nonobstructive disease (35). However, the event rate in patients with nonobstructive disease in our study highlights that atherosclerosis is not “normal.” Similarly, in the PROMISE study, coronary CTA identified patients with nonobstructive disease who were at risk of subsequent events (36). Future studies should assess whether the identification of
coronary artery disease per se can guide treatment changes and improve outcomes for the wider population.

**STUDY LIMITATIONS.** First, the relatively low number of events over 5 years of follow-up limits our power to assess multiple subgroups. This, in part, reflects our selection of the hard clinical endpoint of coronary heart disease death or nonfatal myocardial infarction as well as the low to intermediate risk of the population recruited in the SCOT-HEART trial. Second, the SCOT-HEART study was not designed or powered for this secondary analysis, and our findings are exploratory. Third, we used a simple and pragmatic approach to the identification of adverse plaques that would not greatly add to the time spent analyzing CT scans. Automated software that can identify plaque characteristics may further improve observer variability in the classification of adverse plaques and help standardization. Finally, the trial did encourage the use of secondary preventative therapies in patients found to have either obstructive or nonobstructive disease. This will have inevitably reduced the number of events as well as reduced our ability to identify associations between plaque characteristics and clinical events because they will have been modified by the initiation of antiplatelet and statin therapies.

**CONCLUSIONS**

We have demonstrated that adverse plaque characteristics provide prognostic information out to 5 years, but that this is not independent of plaque burden assessed by coronary artery calcium score. Patients with obstructive disease and adverse plaques have the highest event rates throughout follow-up. This may aid the identification of a subgroup of patients who would benefit from more intensive medical therapy.

**ADDRESS FOR CORRESPONDENCE:** Dr. Michelle C. Williams, University of Edinburgh/BHF Centre for Cardiovascular Science, Chancellor’s Building, SU305, 49 Little France Crescent, Edinburgh EH1 6SU, United Kingdom. E-mail: michelle.williams@ed.ac.uk. Twitter: @imagingmedsci.

**REFERENCES**


35. Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA Intern Med 2017;177:21-3.


**KEY WORDS** atherosclerotic plaque, computed tomography, coronary angiography, coronary artery disease

**APPENDIX** For a supplemental figure and tables, please see the online version of this paper.